Prognostic significance of neutropenia during adjuvant concurrent chemoradiotherapy in early cervical cancer

Journal of Gynecologic Oncology

Volumn 20, Issue 3, 2009, Pages 146-150

  Yun, Hwan Kim ^a   Hyun, Hoon Chung ^a   Jae, Weon Kim ^a   Park, Noh Hyun ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Chemoradiotherapy; Neutropenia; Survival; Uterine cervical cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EARLY CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PELVIS LYMPHADENECTOMY; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; URINARY FREQUENCY; UTERINE CERVIX CANCER;

EID: 77953405063     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2009.20.3.146     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
3. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-1613
4. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358: 781-786 (Pubitemid 32868726)
5. Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, et al. Myeloid growth factors: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5: 188-202. (Pubitemid 46423058)
6. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-237 (Pubitemid 38063629)
7. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80: 1763-1766 (Pubitemid 29389629)
8. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91: 2246-2257 (Pubitemid 32552809)
9. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003; 89: 1837-1842 (Pubitemid 37533256)
10. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6: 669-677 (Pubitemid 41222757)
11. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007; 97: 37-42. (Pubitemid 47012089)
12. Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 2008; 108: 336-341 (Pubitemid 351174291)
13. Kim K, Chie EK, Wu HG, Ha SW, Kim JS, Kim IA, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol 2006; 101: 398-402. (Pubitemid 43729969)
14. Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 1999; 80: 1681.
15. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86: 1297-1302
16. Newell DR. Getting the right dose in cancer chemotherapy: time to stop using surface area? BrJ Cancer 2002; 86: 1207-1208
17. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611 (Pubitemid 26300128)
18. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998; 16: 2297-2298
19. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261
20. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea: a paradigm shift. Cancer Res 2006; 66: 1883-1890 (Pubitemid 43294892)
21. Chung HH, Jang MJ, Jung KW, Won YJ, Shin HR, Kim JW, et al. Cervical cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer 2006; 16: 1833-1838
22. Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007; 25: 85-90. (Pubitemid 350003055)
23. Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, Baumert J, et al. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. Oncology 2006; 71: 32-39 (Pubitemid 46588160)
24. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005; 23: 2191-2200 (Pubitemid 46222235)
25. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 2006; 106: 2327-2336 (Pubitemid 43787655)